Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:41:53.056Z.
Calculation as of: 2026-10-06T19:41:53.056Z.
Quote observation: 2026-10-06T19:39:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc1b6a3b00dabe5b261e15a58cf0fecaa0dcd4715ed4b38f5f86d2c12a5f1f47
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Cellyan Biotechnology Co., Ltd
Market Cap
$1.11M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$894080.00
EV/EBIT Ratio
N/A
TTM Avg
1487.85x
3Y Avg
7742.21x
5Y Avg
7742.21x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.11M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.14M | N/A | 10.71x | 10.71x | 10.71x |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.32M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.33M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.33M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $894080.00 | N/A | 1487.85x | 7742.21x | 7742.21x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.34M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
